MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Net Income
-$1,388K
EPS
-$0.06
Unit: Thousand (K) dollars
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
619
684
538
608
General and administrative
798
1,006
877
827
Total operating expenses
1,417
1,690
1,415
1,435
Loss from operations
-1,417
-1,690
-1,415
-1,435
Interest income
29
36
50
37
Total other income
29
36
50
37
Net loss
-1,388
-1,654
-1,365
-1,398
Basic EPS
-0.06
-0.08
-0.067
-0.07
Diluted EPS
-0.06
-0.08
-0.067
-0.07
Basic Average Shares
21,420,479
21,010,132
20,416,613
20,206,033
Diluted Average Shares
21,420,479
21,010,132
20,416,613
20,206,033
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Interest income$29K (-14.71%↓ Y/Y)Net loss-$1,388K (2.39%↑ Y/Y)Total other income$29K (-14.71%↓ Y/Y)Loss from operations-$1,417K (2.68%↑ Y/Y)Total operatingexpenses$1,417K (-2.68%↓ Y/Y)General andadministrative$798K (-16.88%↓ Y/Y)Research and development$619K (24.80%↑ Y/Y)

Kairos Pharma, LTD. (KAPA)

Kairos Pharma, LTD. (KAPA)